Anesthesia Considerations for Hereditary Spherocytosis
Patients with hereditary spherocytosis (HS) undergoing anesthesia require minimal specific perioperative modifications compared to the general population, as HS is fundamentally different from sickle cell disease and does not carry the same vaso-occlusive or acute chest syndrome risks.
Critical Distinction: HS is NOT Sickle Cell Disease
The provided evidence predominantly addresses sickle cell disease (SCD), which is not applicable to hereditary spherocytosis. HS is a red blood cell membrane disorder causing chronic hemolytic anemia without the sickling, vaso-occlusive crises, or acute chest syndrome seen in SCD. The extensive transfusion protocols and HbS% targets cited in the guidelines 1, 2, 1, 2, 3 are irrelevant to HS patients.
Preoperative Evaluation
Obtain baseline hematologic parameters:
- Complete blood count with attention to hemoglobin level, reticulocyte count
- Indirect bilirubin (typically elevated due to chronic hemolysis)
- Peripheral smear (will show spherocytes)
- Assess for splenomegaly on physical examination
- Screen for cholelithiasis (common comorbidity in HS) 4, 5, 6
Key consideration: Determine disease severity—mild HS patients may have near-normal hemoglobin with compensated hemolysis, while severe cases may have significant anemia requiring transfusion 7, 8.
Transfusion Thresholds
Do NOT use preoperative autologous blood donation in HS patients. Research demonstrates that HS red blood cells lose membrane integrity during standard blood bank storage, with severely shortened post-transfusion survival (median 3.5 days for 4-week-old stored cells vs. 17.5 days for fresh cells) 9.
For transfusion needs:
- Use standard allogeneic transfusion thresholds based on ASA guidelines 10
- Consider intraoperative cell salvage as preferable to preoperative autologous donation 9
- Transfuse based on clinical indicators (symptomatic anemia, hemodynamic instability, significant blood loss) rather than arbitrary hemoglobin targets specific to HS
Intraoperative Management
Standard anesthetic techniques are safe:
- All anesthetic drugs and techniques (general, regional, neuraxial) are appropriate
- No specific drug contraindications exist for HS
- Maintain normal physiologic parameters: normothermia, adequate oxygenation, normovolemia, normal acid-base status
Monitoring:
- Standard ASA monitoring is sufficient
- No special hemolysis monitoring required intraoperatively
- Document blood loss carefully if considering cell salvage
Tourniquet use: No specific contraindications for HS (unlike SCD where controversy exists) 2
Postoperative Management
Standard postoperative care applies:
- Monitor for typical surgical complications
- No increased risk of thrombosis, infection, or wound complications specifically attributable to HS
- Continue chronic hemolysis monitoring if patient has severe disease
For splenectomy patients specifically:
- Ensure preoperative vaccination against encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) 2, 4, 11
- Prophylactic antibiotics perioperatively per institutional protocols
- Long-term infection surveillance post-splenectomy 4, 5, 8
Common Pitfalls to Avoid
- Do not conflate HS with sickle cell disease—the pathophysiology and perioperative risks are entirely different
- Do not arrange preoperative autologous blood donation—stored HS cells have poor viability 9
- Do not apply SCD-specific transfusion protocols (HbS% targets, exchange transfusion) to HS patients
- Do not delay necessary surgery due to mild baseline anemia if the patient is at their compensated baseline
Special Surgical Context
If the patient is undergoing splenectomy for HS treatment (total or partial), this is typically an elective procedure for moderate-to-severe disease with good outcomes 4, 5, 6, 8. The anesthetic considerations remain standard, with attention to potential splenomegaly affecting positioning and surgical access.